Achaogen Inc. (AKAO) Soared To A New High On Phase 3 Study Results

Achaogen Inc. (AKAO) announced Monday morning that its Phase 3 trial of plazomicin met the FDA objective of non-inferiority compared to meropenem and achieved superiority for the European Medicines Agency (EMA) primary efficacy endpoints, in patients with complicated urinary tract infections and acute pyelonephritis.

from RTT - Before the Bell http://ift.tt/2hojYVW
via IFTTT